Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines Company has introduced a 50ml ready-to-use formulation of Argatroban injection as a treatment for thrombosis with heparin-induced thrombocytopenia (HIT) in adult patients.
Subscribe to our email newsletter
Argatroban injection is also indicated as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI).
The Medicines Company senior vice president and chief customer officer Brent Furse said Argatroban is an important drug in the treatment of heparin-induced thrombocytopenia, including in patients with life-threatening thrombosis syndromes.
"Current Argatroban formulations available to hospital pharmacies include a concentrate formula that requires reconstitution to 250ml and a package of two pre-mixed 125ml vials," Furse said.